3D printing is subject to technology. Currently, it is more used in customized services. It has been successfully applied in the medical field. It is mainly used for partial bone replacement. Some hospitals in China have carried out such operations and have achieved success. 3D printing appeared in the mid-1990s and is actually a rapid prototyping device that uses technologies such as photocuring and paper lamination. It works in the same way as a normal printer. The printer is equipped with "printing materials" such as liquid or powder. After connecting with the computer, the printed materials are layered by computer control, and finally the blueprint on the computer is turned into a real object. In recent years, this technology application trend has swept the world quickly after the rise of the United States. Although the industry regards it as the main development direction of the future industry, it is limited by current technology, and large-scale industrial applications have not yet begun. Surgeons are using industrial 3D printers as saviors on the operating table. 3D printing has long been used to make models of jewelry, electronics and automotive parts, but today these industrial printers have been able to make medical supplies such as human bones. Today, the cost of research and development in the pharmaceutical industry, especially the cost of clinical trials, has risen sharply. According to statistics, 95% of experimental drugs were judged to be ineffective or unsafe during human experiments. Now, the good news is coming, and in the near future, 3D printed living tissue may be used for drug testing, making drugs more accurate and effective before entering clinical trials. Biocom 3D printing technology company Organovo announced on January 14, 2014 local time that they will work with the National Institutes of Health (NIH) to help scientists develop safer and more effective drug development tools, making new drug development even more Fast and more reliable. Organovo is also working with the National Center for Advanced Translational Science (NCATS) and the National Institute of Ophthalmology (NEI) to develop better and more clinically predictive tissue models. According to the 3D printing information portal Tiangong, Organovo and NCATS, NEI will use the NOVOGEN bio-printing platform to create a three-dimensional functional living organization with the correct architecture. "Researchers who develop new therapies for patients have used animal models and traditional cell culture models in the past. The main problem is the inability to predict the efficacy and toxicity of drugs to humans," said Organovo CEO Keith Murphy. “The living tissue made by our 3D printers can more realistically replicate the internal tissue activities of the human body. The National Institutes of Health (NIT) has been working hard to find better drug targets, and we hope to create a living tissue model in collaboration with NIT. It can help researchers better demonstrate how drugs work on the human body, so that drugs can be better and more effective before clinical trials. NCATS and NEI will work with Organovo to develop a printable eye tissue. “This technology can provide us with a renewable and easy-to-use source of functional eye tissue,†said Dr. Paul A. Sieving, Director of NEI. “Printable eye tissue can be used to identify diseases and screen for new therapeutics.†NCATS also plans to develop more tissue models to leverage and refine their current tissue microarray and compound screening programs. JIANGSU CLS TECHNOLOGY CORP.LTD , https://www.js-cls.com